BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 38278784)

  • 1. Human coronavirus OC43-elicited CD4
    Dos Santos Alves RP; Timis J; Miller R; Valentine K; Pinto PBA; Gonzalez A; Regla-Nava JA; Maule E; Nguyen MN; Shafee N; Landeras-Bueno S; Olmedillas E; Laffey B; Dobaczewska K; Mikulski Z; McArdle S; Leist SR; Kim K; Baric RS; Ollmann Saphire E; Elong Ngono A; Shresta S
    Nat Commun; 2024 Jan; 15(1):787. PubMed ID: 38278784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.
    Becerra-Artiles A; Nanaware PP; Muneeruddin K; Weaver GC; Shaffer SA; Calvo-Calle JM; Stern LJ
    PLoS Pathog; 2023 Jul; 19(7):e1011032. PubMed ID: 37498934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.
    Becerra-Artiles A; Nanaware PP; Muneeruddin K; Weaver GC; Shaffer SA; Calvo-Calle JM; Stern LJ
    bioRxiv; 2022 Dec; ():. PubMed ID: 36482973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses.
    Schmidt KG; Nganou-Makamdop K; Tenbusch M; El Kenz B; Maier C; Lapuente D; Überla K; Spriewald B; Bergmann S; Harrer EG; Harrer T
    Front Immunol; 2021; 12():627568. PubMed ID: 33995351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.
    Braun J; Loyal L; Frentsch M; Wendisch D; Georg P; Kurth F; Hippenstiel S; Dingeldey M; Kruse B; Fauchere F; Baysal E; Mangold M; Henze L; Lauster R; Mall MA; Beyer K; Röhmel J; Voigt S; Schmitz J; Miltenyi S; Demuth I; Müller MA; Hocke A; Witzenrath M; Suttorp N; Kern F; Reimer U; Wenschuh H; Drosten C; Corman VM; Giesecke-Thiel C; Sander LE; Thiel A
    Nature; 2020 Nov; 587(7833):270-274. PubMed ID: 32726801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional SARS-CoV-2 cross-reactive CD4
    Humbert M; Olofsson A; Wullimann D; Niessl J; Hodcroft EB; Cai C; Gao Y; Sohlberg E; Dyrdak R; Mikaeloff F; Neogi U; Albert J; Malmberg KJ; Lund-Johansen F; Aleman S; Björkhem-Bergman L; Jenmalm MC; Ljunggren HG; Buggert M; Karlsson AC
    Proc Natl Acad Sci U S A; 2023 Mar; 120(12):e2220320120. PubMed ID: 36917669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.
    Woldemeskel BA; Garliss CC; Blankson JN
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4
    Coulon PG; Prakash S; Dhanushkodi NR; Srivastava R; Zayou L; Tifrea DF; Edwards RA; Figueroa CJ; Schubl SD; Hsieh L; Nesburn AB; Kuppermann BD; Bahraoui E; Vahed H; Gil D; Jones TM; Ulmer JB; BenMohamed L
    Front Immunol; 2024; 15():1343716. PubMed ID: 38605956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology.
    Steiner S; Schwarz T; Corman VM; Sotzny F; Bauer S; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
    Front Immunol; 2021; 12():687449. PubMed ID: 34322120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19.
    Yamaguchi T; Shinagawa T; Kobata H; Nakagawa H
    Int J Infect Dis; 2021 Aug; 109():261-268. PubMed ID: 34273512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination.
    Casado JL; Vizcarra P; Martín-Hondarza A; Blasco M; Grandal-Platero M; Haemmerle J; Fernández-Escribano M; Vallejo A
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
    Grifoni A; Weiskopf D; Ramirez SI; Mateus J; Dan JM; Moderbacher CR; Rawlings SA; Sutherland A; Premkumar L; Jadi RS; Marrama D; de Silva AM; Frazier A; Carlin AF; Greenbaum JA; Peters B; Krammer F; Smith DM; Crotty S; Sette A
    Cell; 2020 Jun; 181(7):1489-1501.e15. PubMed ID: 32473127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients.
    Steiner S; Sotzny F; Bauer S; Na IK; Schmueck-Henneresse M; Corman VM; Schwarz T; Drosten C; Wendering DJ; Behrends U; Volk HD; Scheibenbogen C; Hanitsch LG
    Front Immunol; 2020; 11():607918. PubMed ID: 33424856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals.
    Johansson AM; Malhotra U; Kim YG; Gomez R; Krist MP; Wald A; Koelle DM; Kwok WW
    PLoS Pathog; 2021 Dec; 17(12):e1010203. PubMed ID: 34965282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suboptimal SARS-CoV-2-specific CD8
    Habel JR; Nguyen THO; van de Sandt CE; Juno JA; Chaurasia P; Wragg K; Koutsakos M; Hensen L; Jia X; Chua B; Zhang W; Tan HX; Flanagan KL; Doolan DL; Torresi J; Chen W; Wakim LM; Cheng AC; Doherty PC; Petersen J; Rossjohn J; Wheatley AK; Kent SJ; Rowntree LC; Kedzierska K
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24384-24391. PubMed ID: 32913053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.
    Lee E; Sandgren K; Duette G; Stylianou VV; Khanna R; Eden JS; Blyth E; Gottlieb D; Cunningham AL; Palmer S
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33443088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63.
    Saletti G; Gerlach T; Jansen JM; Molle A; Elbahesh H; Ludlow M; Li W; Bosch BJ; Osterhaus ADME; Rimmelzwaan GF
    Sci Rep; 2020 Dec; 10(1):21447. PubMed ID: 33293664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.
    Nguyen-Contant P; Embong AK; Kanagaiah P; Chaves FA; Yang H; Branche AR; Topham DJ; Sangster MY
    mBio; 2020 Sep; 11(5):. PubMed ID: 32978311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses.
    Soni MK; Migliori E; Fu J; Assal A; Chan HT; Pan J; Khatiwada P; Ciubotariu R; May MS; Pereira MR; De Giorgi V; Sykes M; Mapara MY; Muranski PJ
    Front Immunol; 2023; 14():1212203. PubMed ID: 37901229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
    Guo L; Wang Y; Kang L; Hu Y; Wang L; Zhong J; Chen H; Ren L; Gu X; Wang G; Wang C; Dong X; Wu C; Han L; Wang Y; Fan G; Zou X; Li H; Xu J; Jin Q; Cao B; Wang J
    Emerg Microbes Infect; 2021 Dec; 10(1):664-676. PubMed ID: 33734013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.